ERADICATION THERAPY AND WAYS TO IMPROVE IT
Keywords:
Helicobacter pylori, eradication therapy, resistance, antibiotics, clarithromycin, amoxicillin, metronidazole, tetracycline, levofloxacin, proton pump inhibitors, bismuth preparations, tripotassium dicitrate, Maastricht VAbstract
This article discusses data on how, correctly taking into account modern views and possibilities of antibiotic therapy and treatment methods, as well as correct diagnosis of Helicobacter pylori, eradication therapy can be achieved and, most importantly, in what ways this therapy can be improved.
References
B.Kadirov, F. Xamrabayeva. Helicobacter pylori and peptic ulcer disease, as well as views on eradication therapy//New day in medicine. – 2022. – V 1, No. 39. – P. 195–200.
KB Saidovich. Prevalence and Condition of Treatment of Hypertension Disease by Data of Questionnaire//Amaliy va tibbiyot fanlari ilmiy jurnali. – 2023. – Volume 2, No.5. – P. 378–380.
Clinical protocol “Diagnostics and treatment of patients with diseases of the digestive system”: approved. Ministry of Health of the Republic of Uzbekistan 06/01/2017. // Ministry of Health of the Republic of Uzbekistan. – Access mode: http://minzdrav.gov.by/upload/dadvfiles/001077_838640_54gastro.pdf – Access date: 03/29/2018.
Konorev, M. R. Frequency of relapse and reinfection of Helicobacter pylori after a first-line eradication regimen using a probiotic-based immunomodulator as adjuvant therapy: results of a five-year prospective study / M. R. Konorev, T. M. Andronova, M. E. Matveenko // Immunopathology, allergology, infectology. – 2015. – No. 4. – P. 85–92.
Round table. Prevention of cardiovascular pathology: interaction between a cardiologist and a gastroenterologist / ed. T. Yasevich // Healthcare. – 2013. – No. 5. – P. 64–67.
Lazebnik, L. B. The use of probiotics in the eradication of Helicobacter pylori / L. B. Lazebnik, M. N. Rustamov // Classical and applied gastroenterology: materials of the XII Congress of the Scientific Society of Gastroenterologists of Russia, Moscow March 1-2, 2012 .: abstract report – Moscow, 2012. – pp. 18–19.
Leonova, M. V. Genetic polymorphism of CYP2C19 is a predictor of the clinical effectiveness of proton pump inhibitors / M. V. Leonova // Medical Affairs. – 2015. – No. 4. – P. 30–39.
Maev, I. V. Evolution of ideas about the diagnosis and treatment of Helicobacter pylori infection (based on the Maastricht-IV consensus, Florence 2010) / I. V. Maev [et al.] // Bulletin of a practical doctor. – 2012. – No. 1. – pp. 23–30.
Makarenko, E. V. et al. Prevalence of Helicobacter pylori infection in the Vitebsk region / E. V. Makarenko [et al.] // Bulletin of the Vitebsk State Medical University. – 2005. – Volume 4, No. 4. – P. 12–19.
Oceanov, A. E. Statistics of cancer diseases in the Republic of Uzbekistan (2004-2013) / A. E. Oceanov, P. I. Moiseev, L. F. Levin; edited by O. G. Sukonko. – Minsk: Republican Scientific and Practical Medical Center named after. N. N. Alexandrova, 2014. – 382 p.
Osipenko, M. F. “Compliance” of the patient as one of the factors determining the effectiveness of eradication therapy / Osipenko M. F., Livzan M. A., Bikbulatova E. A. // Therapeutic archive. ‒ 2014. ‒ No. 2. – P. 27–31.
Pimanov, S. I. Analysis of the effectiveness of protocols for the eradication of Helicobacter pylori infections / S. I. Pimanov, E. V. Makarenko // Recipe. – 2005. – No. 1. – P. 19–23.
Pimanov, S. I. Antisecretory therapy: from discussions to consensus / S. I. Pimanov, E. V. Makarenko, E. A. Dikareva // Medical news. – 2014. – No. 11. – P. 27–32.
Sablin, O. A. Primary resistance of Helicobacter pylori to antibiotics in St. Petersburg / O. A. Sablin [et al.] // Experimental and clinical pharmacology. – 2012. – No. 8. – P. 18–23.
Stolyarova, V.V. Study of the effect of drugs with immunomodulatory and probiotic effects in peptic ulcer disease and chronic injury / V.V. Stolyarova, N.V. Lebedeva, I.I. Stolyarov // Current problems and achievements in medicine : collection of scientific papers based on the results of the international scientific and practical conference, Samara, April 7–11, 2015 / Innovation Center for the Development of Education and Science; ed. A.F. Apukhtin [and others]. – Samara, 2015. – pp. 218–220.
Fadeenko, G. D. Eradication therapy of Helicobacter pylori in conditions of increasing antibiotic resistance / G. D. Fadeenko, K. A. Sytnik // Suchasna gastroenterology. – 2015. – No. 4. – P. 86–89.
Yanovich, O. O. Assessment of Helicobacter pylori resistance to clarithromycin by PCR in patients with helicobacteriosis / O. O. Yanovich [et al.] // Health. – 2011. – No. 12. – P. 9–12.
Backert, S. Helicobacter pylori research: from bench to bedside / S. Backert, Y. Yamaoka. – Tokyo: Springer, 2016. – 613 p.
Erah P. O. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection / P. O. Erah // The Journal of Antimicrobial Chemotherapy. – 1997. – Vol. 39. – P. 5–12.
Eusebi, L. H. Epidemiology of Helicobacter pylori infection / L. H. Eusebi, R. M. Zagari, F. Bazzoli // Helicoba- cter. – 2014. – Vol. 19, suppl. 1. – P. 1–5. 21. Filipec, K. T. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens / K. T. Filipec [et al.] // Helicobacter. – 2009. – Vol. 14. – P. 29–35.
Fischbach L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori / L. Fischbach, E. L. Evans // Alimentary Pharmacology and Therapeutics. – 2007. – Vol. 26. – P. 343–357. 23. Gisbert, J. P. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies / J. P. Gisbert, A. G. McNicholl // Helicobacter. – 2017. – Vol. 22, iss. 4. – e12392. 24. Graham, D. Y. Helicobacter pylori therapy: a paradigm shift / D. Y. Graham, M. P. Dore // Expert Review of Anti-Infective Therapy. – 2016. – Vol. 14, iss. 6. – P. 577–585.
Graham, D. Y. Helicobacter pylori treatment in the era of increasing antibiotic resistance / D. Y. Graham, L. Fischbach // Gut. – 2010. – Vol. 59. – P. 1143–1153.
Hu, Y. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance / Y. Hu, Y. Zhu, N. H. Lu // Frontiers in Cellular and Infection Microbiology. – 2017. – Vol. 7. – e168.
Karatapanis, S. 7, 10 and 14-days rabeprazole- based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial / S. Karatapa- nis [et al.] // Acta Gastro-enterologica Belgica. – 2011. – Vol. 74. – P. 407–412.
Lee, M. A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori the- rapy / M. Lee [et al.] // Archives of Internal Medicine. – 1999. – Vol. 159, iss. 19. – P. 2312–2316.
Lee, S. J. Clinical application of CYP2C19 phar- macogenetics toward more personalized medicine / S. J. Lee // Frontiers in genetics. – 2013. – Vol. 3. – P. 1–7.
Lv, Z. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis / Z. Lv [et al.] // Experimental and therapeutic medicine. – 2015. – Vol. 9: – P. 707–716.
Malfertheiner, P. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus report / P. Malfertheiner [et al.] // Gut. – 2017. – Vol. 66, iss. 1. – P. 6–30.
O'Connor, J. P. Improving compliance with He- licobacter pylori eradication therapy: when and how? / J. P. O'Connor, I. Taneike, C. O'Morain // Therapeutic Advances in Gastroenterology – 2009. – Vol. 2, iss. 5. – P. 273–279.
Prochorov, A. Gastric cancer in young patients under the age of 30 years / A. Prochorov [et al.] // Journal of Cancer Science and Clinical Oncology. – 2015. – Vol. 1, iss. 2. – e203.
Saracino, I. M. High prevalence of primary an- tibiotic resistance in Helicobacter pylori isolates in Italy / I. M. Saracino [et al.] // Journal of Gastrointestinal and Liver Diseases. – 2012. – Vol. 21. – P. 363–365.
Selgrad, M. Antibiotic susceptibility of Helicobacter pylori in central Germany and its relationship with the number of eradication therapies / M. Selgrad [et al.] // European Journal of Gastroenterology and Hepatology. – 2013. – Vol. 25. – P. 1257–1260.
Thung, I. Review article: the global emergence of Helicobacter pylori antibiotic resistance / I. Thung [et al.] // Alimentary Pharmacology and Therapeutics. – 2016. – Vol. 43, iss. 4. – P. 514–533.
Villoria, A. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobac- ter pylori eradication / A. Villoria [et al.] // Alimentary Pharmacology and Therapeutics. – 2008. – Vol.28, iss. 7. – P. 868–877.
Wang, Y. H. When Helicobacter pylori invades and replicates in the cells / Y. H. Wang, J. J. Wu, H. Y. Lei // Autophagy. – 2009. – Vol. 5, iss. 4. – P. 540–542.
WHO. Adherence to long-term therapies – evidence for action / WHO. – Geneva: World Health Organization, 2003. – 211 p. 40. Zhang Y. X. Primary antibiotic resistance of Heli- cobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study / Y. X. Zhang [et al.] // World Journal of Gastroenterology. – 2015. – Vol. 21. – P. 2786–2792.
